Navigation Links
Nobilon Advances First Vaccine Into Human Trials - Intranasal Influenza Vaccine Begins Phase I Clinical Development
Date:3/13/2009

BOXMEER, Netherlands, March 13 /PRNewswire-FirstCall/ -- Nobilon, the human vaccine business unit of Schering-Plough Corporation (NYSE: SGP), today announced that it has reached an important milestone with the initiation of its first-in-human clinical development program for SCH 900795, a new intranasal Live Attenuated Influenza Vaccine (LAIV) for annual seasonal use.

The candidate vaccine is composed of the three attenuated Influenza viruses recommended by the World Health Organization (WHO) for seasonal vaccine, in an intranasal device. The LAIV differs from most existing influenza vaccines, because it has been designed to offer (1) single-dose intranasal delivery, (2) advanced cell culture manufacturing technology and (3) potential earlier and broader protection against infection by influenza viruses.

The Phase I study consists of a randomized, double-blind, placebo-controlled, rising single-dose design and will include a total of 120 healthy volunteers. The primary objective of the Phase I program is to investigate the safety, tolerability and immunogenicity of escalating doses of SCH 900795 in adult men and women.

"I am pleased to announce the start of the first clinical development program of Nobilon," said Gelmer Leibbrandt, general manager of Nobilon. "This is an important milestone in the young history of our company." Han van den Bosch, Director R&D, stated: "We are encouraged by the positive results obtained in the pre-clinical development of our candidate vaccine so far and we believe that this vaccine has the potential to become an important tool in the prevention against seasonal Influenza illness."

The initiation of the clinical development program of SCH 900795 represents Nobilon's commitment to bringing innovative vaccines for human health to the market using state-of-the-art technologies.

About Influenza

Influenza (flu) is a contagious disease caused by the influenza virus. Influenza is a significant cause of morbidity and mortality and seasonal epidemics are responsible for approximately 40,000 deaths and over 100,000 hospitalizations annually in the US. Influenza infection in children causes a significant increase in both medically attended illness as well as hospitalizations. Mortality due to influenza generally affects aging adults. Inactivated, parenterally administered influenza vaccines have been available since the mid-1940s and effectively prevent influenza illness in healthy adults. Vaccination of elderly generally has a lower impact on prevalence, but is up to 80% effective in preventing death. Nevertheless, current inactivated influenza vaccines have limitations and are underutilized. Intramuscular vaccination with needles is an important barrier for the acceptance of annual influenza vaccination, which may be overcome by intranasal application. Moreover, Live Attenuated Influenza Vaccine (LAIV) is expected to be more effective in inducing local and cellular immunity and as such may be more efficacious in eliciting protection.

About SCH 900795

Nobilon acquired in 2004 the majority of rights to develop, commercialize and manufacture the LAIV technology from Australian company BioDiem, which had acquired these rights from the Institute of Experimental Medicine in St. Petersburg, Russian Federation. SCH 900795 could offer several improvements over most current vaccines such as single-dose intranasal spray delivery, improved convenience and earlier and broader protection. Moreover, SCH 900795 is manufactured using state-of-the-art cell culture technology. Cell-based vaccine production offers important advantages over egg-based production such as consistency and flexibility in production, reduced risk of microbial contamination, a more homogenous viral yield, and usability for subjects with egg allergies.

About Nobilon

Nobilon International BV, a part of Schering-Plough Corporation, was founded in 2003 and was acquired through the Organon BioSciences acquisition in 2007. It has production and R&D facilities in Boxmeer and Oss, the Netherlands. The biotechnology company is dedicated to develop, produce and market human vaccines, building on existing expertise within Schering-Plough. One of its core expertises is large-scale cell culture production of viruses, including influenza. For more information, go to the website www.nobilon.com.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Mardil Inc. Advances Its Novel Cardiac Device to First-In-Human Trials for Mitral Valve Regurgitation
2. Advances in Science and Treatment of Pain Presented at 25th Annual American Academy of Pain Medicine Meeting January 28 - 31, 2009
3. Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting
4. S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis
5. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
6. MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine
7. Anpath Group, Inc. Advances Relationship With the Washington Metropolitan Area Transit Authority (Metro)
8. Despite Advances in the Accuracy of CT Colonography in Detecting Polyps, Digestive Health Experts Urge Patients to Consider Risks and Realities
9. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
10. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
11. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... and FAIRFIELD, N.J. , ... and Medimetriks Pharmaceuticals, Inc. (Medimetriks) today announced that they ... development and commercialization rights for OPA-15406 in the U.S. ... also provides manufacturing rights.  OPA-15406 is a topical, non-steroidal ... atopic dermatitis. --> --> ...
(Date:2/8/2016)... -- --> --> ... Market by Product (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) ... Gynecology) - Global Forecasts to 2020", published by MarketsandMarkets, ... period of 2015 to 2020. The market is expected ... 10.5% from 2015 to 2020. Browse 73 ...
(Date:2/8/2016)... , Feb. 8, 2016 In a historic vote among its ... to construct a medical cannabis cultivation facility and dispensary on tribal land ... New York as a provider for patients in the state,s ... as a provider for patients in the state,s Medical Cannabis ... (34) to approve the project and pursue designation from the ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... Delta Dental of California and ... pancreatic cancer. , Gary D. Radine, who recently retired as president and CEO of ... Society’s 2015 CEO of the Year , helped lead the effort to raise ...
(Date:2/8/2016)... ... February 08, 2016 , ... Eating disorders and post-traumatic stress ... women and men with eating disorders report a history of trauma, research suggests ... of an eating disorder. , At the 2016 iaedp Symposium, the workshop, ...
(Date:2/8/2016)... ... February 08, 2016 , ... GrassrootsHealth published data from ... type 2 diabetes in the GrassrootsHealth cohort with substantially higher vitamin D levels ... in public health,” states Carole Baggerly, Director of GrassrootsHealth, “the safety and ...
(Date:2/8/2016)... ... February 08, 2016 , ... Joshua ... on how healthcare companies can use newly released government data on populations and ... population and intervene and capture the value they create to succeed in new ...
(Date:2/8/2016)... ... February 08, 2016 , ... According to research ... U.S. require dental technicians to be certified or obtain continuing education. To increase ... the “What’s In Your Mouth?” campaign to inform dentists and patients about the ...
Breaking Medicine News(10 mins):